Hypereosinophilic Syndrome — RACP Adult Medicine MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Hypereosinophilic syndrome
Persistent marked eosinophilia (>1.5 × 10⁹/L for >6 months) with organ damage (endomyocardial fibrosis) and FIP1L1-PDGFRA fusion is myeloid-type hypereosinophilic syndrome. This specific fusion responds dramatically to low-dose imatinib (100 mg/day). Without treatment, eosinophilic infiltration causes progressive cardiac, pulmonary, GI, and neurological damage.
Reference: WHO – 2022 – Eosinophilic Neoplasms; ELN 2024